Telix Pharmaceuticals Limited Sponsored ADR TLX 深 沪
等待开盘 08-28 09:30:00 美东时间
11.375
+0.245
+2.20%
华盛通- 最 高11.38
- 今 开11.32
- 成交量 7.38万股
- 最 低 11.27
- 昨 收 11.13
- 总市值 38.54亿
- 52周最高 12.48
- 市盈率 静 --
- 换手率 0.02%
- 52周最低 6.28
- 委 比 64.14%
- 总股本 3.39亿
- 历史最高 30.36
- 量 比 0.32
- 振 幅 0.99%
- 历史最低 6.28
- 每 手 1
- 风险率 1.44%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多美股大行评级 | 塔吉特获13家大行上调目标价；Moderna携手默沙东齐获大行上调目标价
今日重点评级关注：康托·菲茨杰拉德：维持Ultragenyx Pharmaceutical"超配"评级，目标价从96美元升至103美元；Canaccord Genuity：维持Ultragenyx Pharmaceutical"买入"评级，目标价从81美元升至83美元
08-21 11:40
Wedbush Reiterates Outperform on Telix Pharmaceuticals, Maintains $22 Price Target
Wedbush analyst David Nierengarten reiterates Telix Pharmaceuticals (NASDAQ:TLX) with a Outperform and maintains $22 price target.
08-21 00:47
Telix Pharmaceuticals Announces That The First Patient Has Been Dosed With TLX250-Tx In The LUTEON Study
Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ:TLX, "Telix") today announced that the first patient has been dosed with TLX250-Tx (lutetium-177 (177Lu) girentuximab tetraxetan) in the LUTEON study, the first radiopharmaceutical therapy to enter Phase 3 development for ccRCC. LUTEON is a randomized,...
07-21 05:14
美股大行评级 | 最高800美元！16家大行首予SpaceX"买入"或"超配"评级；奥本海上调康宁目标价从210美元升至230美元
今日重点评级关注：Canaccord Genuity：维持AtaiBeckley"买入"评级，目标价从15美元升至17美元；Truist Securities：维持NUVATION BIO"买入"评级，目标价从12美元升至13美元
07-08 15:31
美股大行评级 | 高盛上调AMD目标价从450美元升至640美元；伯恩斯坦上调阿斯麦目标价从1971美元升至2623美元
今日重点评级关注：Roth Capital：维持Nuvectis Pharma"买入"评级，目标价从20美元升至33美元；摩根士丹利：维持GXO Logistics"超配"评级，目标价从75美元升至78美元
07-07 11:34
Wedbush Reiterates Outperform on Telix Pharmaceuticals, Maintains $22 Price Target
Wedbush analyst David Nierengarten reiterates Telix Pharmaceuticals (NASDAQ:TLX) with a Outperform and maintains $22 price target.
07-06 20:46
Telix Pharmaceuticals Signs MoU With United Imaging Healthcare North America To Evaluate A U.S. Research Collaboration On Advancing Integrated Theranostics Solutions
Partnership to evaluate Telix's innovative precision medicine products and candidates in combination with United Imaging's advanced scanner platforms.Initial focus on TLX101-Px (Pixclara®1, Floretyrosine F 18) in
06-02 19:17
Why Is Regeneron Stock Sinking Monday?
Regeneron melanoma combo trial missed its main goal against Keytruda despite longer progression-free survival in the high-dose arm.
05-18 18:28
Telix Pharma Enters Into LOI To Pursue Collaborations With EDAP And Profound Medical To Explore Investigational Use Of Telix's PSMA-PET1 Imaging Agents Gozellix And Illuccix With Robotic HIFU, And Other Image-Guided Therapies To Treat Prostate Cancer
Telix to partner with companies developing advanced minimally invasive and image-guided ablative technologies for prostate cancer.Initial focus on patient selection, treatment planning and post-treatment monitoring;
05-15 18:33
Telix Pharmaceuticals' TLX250-Px PET/CT Demonstrates High Predictive Accuracy Across All Renal Cancer Subtypes In Phase 3 ZIRCON Trial Analysis
Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ:TLX, "Telix") today announces the publication of a new independent analysis of Phase 3 ZIRCON trial data in European Urology1, demonstrating that TLX250-Px
05-05 05:03
